Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06285539 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

Study acronym: DRIMID
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study completion date: Dec 2026 to Dec 2027v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2024 to Mar 12, 2024
    • Site details revised at 6 of 6 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) is limited due to small patient populations. Patients with Behçet's disease (BD), idiopathic inflammatory myopathy (IIM, also known as myositis) and IgG4-related disease (IgG4-RD) are treated with high-dosed glucocorticoids, methotrexate, azathioprine and mycophenolate mofetil, mostly for long periods of time with attendant risks of long-term toxicity, including infections. Therefore, there is an urgent need for new, more specific anti-inflammatory therapies such as targeted synthetic and biological disease-modifying antirheumatic drugs. Due to the role of type 1 interferon in both BD, IIM and IgG4-RD, JAK-STAT inhibition may be a promising treatment strategy in these conditions, because JAK1 is critical for the signal transduction of pro-inflammatory cytokine receptors. Previous research showed that JAK1 inhibition reduces activation of type 1 interferon-regulated proteins and key chemokines that control tissue inflammation.
Trial Details
NCT Number NCT06285539
Lead Sponsor UMC Utrecht
Collaborators: Alfasigma S.p.A., ReumaNederland, Autoimmune Research and Collaboration Hub
Conditions
(from sponsor)		 Behcet's Disease, Idiopathic Inflammatory Myopathies, IgG4-related Disease
Related terms Behcet Syndrome, Immunoglobulin G4-Related Disease, Myositis
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov